ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 08 Feb 2023
Last Updated on 08 Feb 2023
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended palivizumab for inclusion on the MOH List of Subsidised Drugs for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease, because it does not represent a cost-effective use of healthcare resources at the price proposed by the company.

Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus (Published 8 Feb 2023) PES Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus (Published 8 Feb 2023)